Advertisement

Scientific Basis for Ayurvedic Medicinal Plants Against Alzheimer’s Disease

  • Atanu Bhattacharjee
  • Raja Chakraborty
  • Saikat Sen
Chapter

Abstract

Alzheimer’s disease (AD) is a degenerative brain disorder that manifests as a progressive deterioration of memory and mental function—a state of mind commonly referred to as “dementia” and causes changes in personality and behavior. AD was first described in 1906 by German neuropsychiatries Prof. Alois Alzheimer. Major pathological hallmarks of AD are characterized by deposition of abnormal amyloid β protein plaques, formation of neurofibrillary tangles of tau protein, and decline in cholinergic neurotransmission in brain. During the last decade, significant growth in Alzheimer’s prevalence has ignited the importance of more researches in the search of new medicine. One of the major clinical advances in the treatment of AD has been the use of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors to alleviate ACh level in brain although cholinergic compounds with nicotinic and muscarinic agonist properties also have attracted some interest. At present, there are very limited medications available to treat AD and most of the treatment is available only to delay the progression of symptoms and symptomatic relief for a short period of time. Medicinal plants represent a great deal of untapped reservoir of natural medicines and a potential source of natural AChE inhibitors. The structural diversity of their phytoconstituents makes them a valuable source of novel lead compounds for the quest of drugs to treat AD. Therefore, systematic ethnopharmacological screening of these plants may provide useful leads in the discovery of new drugs for AD therapy. With this background, a systematic review is prepared to bring forth an updated knowledge in various phytoextracts and their derivatives along with their possible action on cholinergic nervous system to ease AD therapy. Electronic database was used for searching the information related to studies performed in plants during last decades.

Keywords

Alzheimer’s disease Acetylcholine Cholinesterase inhibition Medicinal plant 

References

  1. Abhang RY. Medhya rasayana: past, present and future. Deerghayu Int. 1987;4:8–18.Google Scholar
  2. Adewusi EA, Steenkamp V. In vitro screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Southern Africa. Asian Pac J Trop Med. 2011;5(2):829–35.CrossRefGoogle Scholar
  3. Ahirwar S, Tembhre M, Gour S, Namdeo A. Anticholinesterase efficacy of Bacopa monnieri against the brain regions of rat—a novel approach to therapy for Alzheimer’s disease. Asian J Exp Sci. 2012;26(1):65–70.Google Scholar
  4. Ahmed T, Gilani AH. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer’s disease. Pharmacol Biochem Behav. 2009;91:554–9.PubMedCrossRefPubMedCentralGoogle Scholar
  5. Aisen PS. Anti-inflammatory agents in Alzheimer’s disease. Curr Neurol Neurosci Rep. 2002a;2:405–52.PubMedCrossRefPubMedCentralGoogle Scholar
  6. Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer’s disease. J Pain Symptom Manag. 2002b;23:S35–42.CrossRefGoogle Scholar
  7. Akhlaq AF, Tahira F, Anil M, Jolin Hwee-Jing O, Wei-Yi O. Ayurvedic medicine for the treatment of dementia: mechanistic aspects. Evid Based Complement Alternat Med. 2018;40(2):1–11.Google Scholar
  8. Akinrimisi ED, Ainwannde AI. Effect of aqueous extract of Eugenia caryolphyllus on brain acetylcholinesterase in rats. West Afr J Pharmacol Drug Res. 1975;2:127–33.PubMedPubMedCentralGoogle Scholar
  9. Amod PK, Laurie AK, Girish JK. Herbal complement inhibitors in the treatment of neuroinflammation. Ann N Y Acad Sci. 2005;1056:413–29.CrossRefGoogle Scholar
  10. Anderson RN. Deaths: leading causes for 2000. Natl Vital Stat Rep. 2002;50:1.PubMedPubMedCentralGoogle Scholar
  11. Anil K, Samrita D, Atish P. Neuroprotective effects of Centella asiatica against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress. Int J Alzheimer’s Dis. 2009;9:1–8.Google Scholar
  12. Atanu B, Shastry CS, Saha S. Nootropic activity of Crataeva nurvala Buch-ham against scopolamine induced cognitive impairment. EXCLI J. 2015;14:335–45.Google Scholar
  13. Bahr BA, Bendiske J. The neuropathogenic contributions of lysosomal dysfunction. J Neurochem. 2002;83:481–92.PubMedCrossRefPubMedCentralGoogle Scholar
  14. Bajaj S, Vohora SB. Anticataleptic, anti-anxiety and anti-depressant activity of gold preparation used in Indian systems of medicine. Indian J Pharmacol. 2000;32:339.Google Scholar
  15. Bajaj S, Ahamad I, Fatima M, Raisuddin S, Vohora SB. Immunomadulatory activity of a Unani gold preparation used in Indian system of medicine. Immunopharmacol Immunotoxicol. 1999;21:151.PubMedCrossRefPubMedCentralGoogle Scholar
  16. Berrino F. Western diet and Alzheimer’s disease. Epidemiol Prev. 2002;26:107.PubMedPubMedCentralGoogle Scholar
  17. Bhattacharya SK, Kumar A. Effect of glycowithanolides from Withania somnifera on an animal model of Alzheimer’s disease and perturbed central cholinergic markers of cognition in rats. Phytother Res. 1995;9:110–6.CrossRefGoogle Scholar
  18. Boral GC, Gautam B, Anjan B, Das NN, Nandi PS. Geriforte in anxiety neurosis. Indian J Psychiatry. 1989;31(3):258–60.PubMedPubMedCentralGoogle Scholar
  19. Bush AI. The metallobiology of Alzheimer’s disease. Trends Neurosci. 2003;26(4):207–14.PubMedCrossRefPubMedCentralGoogle Scholar
  20. Carlo C, William LG, Michael L, Dale K, Kerry B, Barry O. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008;14(6):707–13.CrossRefGoogle Scholar
  21. Chatellier G, Lacomblez L. Tacrine (teterahydroaminoacridine; THA) and lecithine in senile dementia of the Alzheimer type: a multicenter trial. Br Med J. 1990;300:495.CrossRefGoogle Scholar
  22. Clegg BJ, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N. Clinical and cost effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer’s disease: a systematic review. Int J Technol Assess Health Care. 2002;18:497.PubMedCrossRefPubMedCentralGoogle Scholar
  23. Colucci L, Bosco M, Ziello AR, et al. Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review. J Exp Pharmacol. 2012;4:163–72.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Dahanukar SA, Kulkarni RA, Rege NN. Pharmacology of medicinal plants and natural products. Indian J Pharmacol. 2000;32:S81–S118.Google Scholar
  25. Dash SC, Tripathi SN, Singh RH. Clinical assessment of medhya drugs in the management of psychosis (unmada). Ancient Sci Life. 1983;3:77–83.Google Scholar
  26. Divya SV, Lakshmi CM. Alzheimer’s disease. Scientific basis for Ayurvedic medicines. New York: CRC Publishers; 2007.Google Scholar
  27. Doraiswamy PM. Non-cholinergic strategies for treating and preventing Alzheimer’s disease. CNS Drugs. 2002;16:24.CrossRefGoogle Scholar
  28. Dwivedi KK, Singh RH. A clinical study of medhya rasayana therapy in the management of convulsive disorder. J Res Ayurveda Siddha. 1978;13:97.Google Scholar
  29. Fernando GP. Brain foods: the effects of nutrients on brain function. Nat Rev Neurosci. 2008;9(7):568–78.CrossRefGoogle Scholar
  30. Frawley D. Ayurvedic Healing. Delhi, India: Motilal Banarsidass Publishers; 1989.Google Scholar
  31. Gelb DJ. Measurement of progression in Alzheimer’s disease: a clinician perspective. Stat Med. 2000;19:1390–8.CrossRefGoogle Scholar
  32. Ghosh AK, Osswald HL. BACE1 (β-Secretase) inhibitors for the treatment of Alzheimer’s disease. Chem Soc Rev. 2014;43(19):6765–813.  https://doi.org/10.1039/c3cs60460h.CrossRefPubMedPubMedCentralGoogle Scholar
  33. Gohil KJ, Patel JA. A review on Bacopa monniera: current research and future prospects. Int J Green Pharma. 2010;2:1–9.CrossRefGoogle Scholar
  34. Gupta BM, Bala A. Alzheimer’s disease research in India: a scientometric analysis of publications output during 2002–11. Res Neurol Int J. 2013;2013:11.  https://doi.org/10.5171/2013.204542.CrossRefGoogle Scholar
  35. Habibur R, Muralidharan P, Anand M. Inhibition of AChE and antioxidant activities are probable mechanism of Nardostacys Jatamansi DC in sleep deprived Alzheimer’s mice model. Int J Pharma Tech Res. 2011;3(3):1807–16.Google Scholar
  36. Handa SS, Bhargava VK. Effect of BR 16-A (Mentat) on cognitive deficits in aluminum treated and aged rats. Indian J Pharmacol. 1997;28:258–64.Google Scholar
  37. Harvey AL. Natural products in drug discovery. Drug Discov Today. 2008;13:894–901.PubMedCrossRefPubMedCentralGoogle Scholar
  38. Howes MJ, Houghton PJ. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav. 2003;75:513–27.PubMedCrossRefPubMedCentralGoogle Scholar
  39. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148(6):1204–22.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Huang W, Zhang X, Chen W. Role of oxidative stress in Alzheimer’s disease. Biomed Rep. 2016;4(5):519–22.PubMedPubMedCentralCrossRefGoogle Scholar
  41. Ingkaninan K, Phengpa P, Yuenyongsawad S, Khorana N. Acetylcholinesterase inhibitors from Stephania venosa tuber. J Pharm Pharmacol. 2006;58:695–700.PubMedCrossRefPubMedCentralGoogle Scholar
  42. Iyer MR, Pal SC, Kasture VS, Kasture SB. Effect of Lawsonia inermis on memory and behaviour mediated via monoamine neurotransmitters. Ind J Pharmacol. 1998;30:181–5.Google Scholar
  43. Jagdeep SD, Prasad DN, Avinash CT, Rajiv G. Role of traditional medicine in neuropsychopharmacology. Asian J Pharm Clin Res. 2009;2(2):72–6.Google Scholar
  44. Jemima J, Bhattacharjee P, Singhal RS. Melatonin—a review on the lesser known potential nutraceutical. Int J Pharm Sci Res. 2011;2(8):1975–87.Google Scholar
  45. Jian-zhi W, Ze-fen W. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sinica. 2006;27(1):41–9.CrossRefGoogle Scholar
  46. Jivad N, Rabiei Z. A review study on medicinal plants used in the treatment of learning and memory impairments. Asian Pac J Trop Biomed. 2014;4:780–9.CrossRefGoogle Scholar
  47. Kar S, Slowikowski SPM, Westaway D, Mount HTJ. Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease. J Psychiatry Neurosci. 2004;29(6):427–41.PubMedPubMedCentralGoogle Scholar
  48. Kashmira JG, Jagruti P, Anuradha KG. Pharmacological review on Centella asiatica: a potential herbal cure-all. Ind J Pharma Sci. 2010;72(5):546–56.CrossRefGoogle Scholar
  49. Keyvan D, Damien Dorman HJ, Heikki V, Raimo H. Plants as potential sources for drug development against Alzheimer’s disease. Int J Biomed Pharm Sci. 2007;1(2):83–104.Google Scholar
  50. Khare CP. Indian medicinal plants an illustrated dictionary. Berlin: Springer; 2007.Google Scholar
  51. Kulkarni SK, Verma A. BR 16-A (Mentat): a herbal preparation improves learning and memory performance in mice. PRO. 1994;3(222):28.Google Scholar
  52. Lemstra AW, Eikelenboom P, Van Gool WA. The cholinergic deficiency syndrome and its therapeutic implications. Gerontology. 2003;49:55.PubMedCrossRefPubMedCentralGoogle Scholar
  53. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, McDowell I. Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian study of health and aging. Am J Epidemiol. 2002;156:445–52.PubMedCrossRefPubMedCentralGoogle Scholar
  54. Mahesh G, Tasneem S. Biomarker controversies and diagnostic difficulties in Alzheimer’s disease. Am J Phytomed Clin Therap. 2014;2(4):463–8.Google Scholar
  55. Manyam BV. Dementia in Ayurveda. J Altern Complement Med. 1999;5:81–8.PubMedCrossRefPubMedCentralGoogle Scholar
  56. Maya M, Sarada S. In vitro screening for anti-cholinesterase and antioxidant activity of methanolic extracts of Ayurvedic medicinal plants used for cognitive disorders. PLoS One. 2014;9(1):e86804.CrossRefGoogle Scholar
  57. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev. 2000;5:334–46.PubMedPubMedCentralGoogle Scholar
  58. Mukherjee PK, Kumar V, Mal M, Houghton PJ. Acetylcholinesterase inhibitors from plants. Phytomedicine. 2007;14:289–300.PubMedCrossRefPubMedCentralGoogle Scholar
  59. Muralidharan P, Balamurugan G, Venu B. Cerebroprotective effect of Glycyrrhiza glabra Linn. root extract on hypoxic rats. Bangladesh J Pharmacol. 2009;4:60–4.Google Scholar
  60. Nillert W, Pannangrong W, Welbat JU. Neuroprotective effects of aged garlic extract on cognitive dysfunction and neuroinflammation induced by β-amyloid in rats. Nutrients. 2017;9:24–36.PubMedCentralCrossRefGoogle Scholar
  61. Orhan I, Kartal M, Naz Q, Ejaz A, Yilmaz G, Kan Y, et al. Antioxidant and anticholinesterase evaluation of selected Turkish Salvia species. Food Chem. 2007;103:1247–54.CrossRefGoogle Scholar
  62. Patel VS, Jivani NP, Patel SB. Medicinal plants with potential nootropic activity: a review. Res J Pharm Bio Chem Sci. 2014;5(1):1–11.Google Scholar
  63. Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS. Medicinal plants and Alzheimer’s disease: from ethnobotany to phytotherapy. J Pharm Pharmacol. 1999;51:527–33.PubMedCrossRefPubMedCentralGoogle Scholar
  64. Perry NSL, Houghton PJ, Theolad AE, Jenner P, Perry EK. In vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol. 2000;52:895–902.PubMedCrossRefPubMedCentralGoogle Scholar
  65. Perry NSL, Houghton PJ, Sampson J, Theolad AE, Hart S, Lis-balchin M. In vitro activities of Salvia lavandulaefolia (Spanish Sage) relevant to treatment of Alzheimer’s disease. J Pharm Pharmacol. 2001;53:1347–56.PubMedCrossRefPubMedCentralGoogle Scholar
  66. Philomena G. Concerns regarding the safety and toxicity of medicinal plants—an overview. J Appl Pharma Sci. 2011;1(6):40–4.Google Scholar
  67. Prachi S, Lakshmayya L, Vinod SB. Anti-Alzheimer activity of isolated karanjin from Pongamia pinnata (L.) pierre and embelin from Embelia ribes Burm.f. Int Quarterly J Res Ayurveda. 2017;38(1):76–81.CrossRefGoogle Scholar
  68. Prakash R, Sandhya E, Ramya N, Dhivya R, Priyadarshini M, Sakthi Priya B. Neuroprotective activity of ethanolic extract of Tinospora cordifolia on LPS induced neuroinflammation. Transl Biomed. 2017;8(4):135–42.Google Scholar
  69. Prerna U, Vikas S, Mushtaq A. Therapy of Alzheimer’s disease: an update. Afr J Pharm Pharmacol. 2010;4(6):408–21.Google Scholar
  70. Puchchakayala G, Akina S, Thati M. Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress. Int J Alzheimers Dis. 2012;12:1–8.Google Scholar
  71. Rammohan VR, Olivier D, Varghese J, Dale EB. Ayurvedic medicinal plants for Alzheimer’s disease: a review. Alzheimers Res Ther. 2012;4(22):1–12.Google Scholar
  72. Rhee IK, Meent MV, Ingkaninan K, Verpoorte R. Screening for acetylcholinesterase inhibitors from Amaryllidaceae using silica gel thin-layer chromatography in combination with bioactivity staining. J Chromatogr. 2001;915:217–23.CrossRefGoogle Scholar
  73. Rinne JO, Kaasinen V, Jarvenpaa T, Någren K, Roivainen A, Yu M, et al. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer’s disease. Neurol Neurosurg Psychiatry. 2003;74:113–5.CrossRefGoogle Scholar
  74. Roberts SB. Gamma-secretase inhibitors and Alzheimer’s disease. Adv Drug Deliv Rev. 2002;54:1579–82.PubMedCrossRefPubMedCentralGoogle Scholar
  75. Satyavati GV, Gupta AK, Tandon N, Seth SD. Medicinal plants of India, Vol. 2. New Delhi, India: Indian Council of Medical Research; 1987.Google Scholar
  76. Schiloers R, Liermann A, Bhattacharya SK, Kumar A, Ghoshal S, Rich V. Systemic administration of defined extracts from Withania Somnifera (Indian ginseng) and shilajit differentially affects cholinergic but not glutaminergic and gabaergic markers in rat brain. Neurochem Int. 1997;30:181.CrossRefGoogle Scholar
  77. Schneider LS. New therapeutic approaches to Alzheimer’s disease. Psychiatry. 1996;57:30–6.Google Scholar
  78. Sharma PC, Yelne MB, Dennis TJ. Database on medicinal plants used in Ayurveda and Sidha. 1st ed. New Delhi: CCRAS, Dept. of AYUSH, Ministry of Health and Family Welfare, Govt. of India; 2005.Google Scholar
  79. Singh RH, Sinha BN, Sarkar FH, Udupa KN. Comparative biochemical studies on the effect of four Medhya Rasayana drugs described by Caraka on some central neurotransmitters in normal and stressed rats. J Indian Med Yoga Homeopathy. 1979;14:7–14.Google Scholar
  80. Soumyanath S, Zhong Y, Henson E, et al. Centella asiatica extract improves behavioral deficits in a mouse model of Alzheimer’s disease: investigation of a possible mechanism of action. Int J Alzheimers Dis. 2012;12:381–94.Google Scholar
  81. Spiegel R. Rivastigmine: a review of its clinical effectiveness. Rev Neurol. 2002;35:859.PubMedPubMedCentralGoogle Scholar
  82. Talic S, Dragicevic I, Corajevic L, Martinovic BA. Acetylcholinesterase and butyrylcholinesterase inhibitory activity of extracts from medicinal plants. Bulletin Chemists Technol Bosnia Herzegovania. 2014;43:11–4.Google Scholar
  83. Uma G, Uma Maheswari S. Neuroprotective effects of polyherbal formulation (Indian Noni) on scopolamine-induced memory impairment in mice. Int J Pharm Pharm Sci. 2014;6(1):354–7.Google Scholar
  84. Urbain A, Marston A, Queiroz EF, Ndjoko K, Hostettmann K. Xanthones from Gentiana campestris as new acetylcholinesterase inhibitors. Planta Med. 2004;70:1011–4.PubMedCrossRefPubMedCentralGoogle Scholar
  85. Vaidya AB. The status and scope of Indian medicinal plants acting on the central nervous system. Indian J Pharmacol. 1997;29(S340):228–34.Google Scholar
  86. Vinutha B, Prashanth D, Salma K, Sreeja SL, Pratiti D, Padmaja R, et al. Screening of selected Indian medicinal plants for acetylcholinesterase inhibitory activity. J Ethnopharmacol. 2007;109:359–63.PubMedCrossRefPubMedCentralGoogle Scholar
  87. Vladimir V, Sophia R. Results of beta secretase-inhibitor clinical trials support amyloid precursor protein-independent generation of beta amyloid in sporadic Alzheimer’s disease. Med Sci (Basel). 2018;6(2):45–58.Google Scholar
  88. Vohora SB, Kim HS, Shah SA, Khanna T, Dandiya PC. CNS and adaptogenic effects of Siddh Makardhwaja: an Ayurvedic mercury preparation, in trace elements in nutrition and health. New Delhi, India: Jamia Hamdard and Wiley Eastern Ltd.; 1995.Google Scholar
  89. Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis. J Neural Transm. 2009;116(4):457–65.PubMedCrossRefPubMedCentralGoogle Scholar
  90. Zhang F, Jiang L. Neuroinflammation in Alzheimer’s disease. Neuropsychiatr Dis Treat. 2015;11:243–56.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Atanu Bhattacharjee
    • 1
  • Raja Chakraborty
    • 1
  • Saikat Sen
    • 1
  1. 1.Department of PharmacyAssam Down Town UniversityGuwahatiIndia

Personalised recommendations